Skip to main content

Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?

Current Cardiology Reports volume 20, Article number: 105 (2018) Cite this article

Abstract

Purpose of Review

A number of recent observational analyses have assessed clinical outcomes associated with digoxin use in patients with atrial fibrillation. In this review, we review these data and provide suggestions on the contemporary use of digoxin in patients with atrial fibrillation as supported by the recent evidence.

Recent Findings

Observational data from clinical trials and registries have provided variable results on the safety and efficacy of chronic digoxin use in patients with atrial fibrillation. In general, results have been consistent with an associated increase in adverse clinical outcomes with digoxin use in atrial fibrillation patients without heart failure. In atrial fibrillation patients with heart failure, while the weight of evidence suggested an associated risk with digoxin therapy, the results are inconsistent.

Summary

In patients with atrial fibrillation without heart failure, digoxin should generally be avoided. In atrial fibrillation patients with heart failure, digoxin should generally be reserved for patients that do not achieve adequate rate control or are not tolerant of other rate control therapies.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.

    Article  Google Scholar 

  2. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.

    Article  PubMed Central  Google Scholar 

  3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

    CAS  Article  Google Scholar 

  4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    CAS  Article  PubMed Central  Google Scholar 

  5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

    CAS  Article  PubMed Central  Google Scholar 

  6. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–8.

    CAS  Article  PubMed Central  Google Scholar 

  7. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34(20):1489–97.

    CAS  Article  PubMed Central  Google Scholar 

  8. Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart. 2008;94(2):191–6.

    CAS  Article  Google Scholar 

  9. Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385(9985):2363–70.

    CAS  Article  PubMed Central  Google Scholar 

  10. Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C et al. Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017;6(7).

  11. • Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063–74. This analysis from the ARISTOTLE trial showed in atrial fibrillation patients taking digoxin, the risk of death was independently associated with serum digoxin concentrations.

    CAS  Article  PubMed Central  Google Scholar 

  12. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014;11(9):1543–50.

    Article  PubMed Central  Google Scholar 

  13. Hallberg P, Lindback J, Lindahl B, Stenestrand U, Melhus H, group R-H. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol. 2007;63(10):959–71.

    CAS  Article  PubMed Central  Google Scholar 

  14. Friberg L, Hammar N, Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart. 2010;96(4):275–80.

    CAS  Article  PubMed Central  Google Scholar 

  15. Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015;132(17):1604–12.

    CAS  Article  PubMed Central  Google Scholar 

  16. • Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8. This article represents one of the largest observational studies to date assessing digoxin use in patients with atrial fibrillation.

    CAS  Article  PubMed Central  Google Scholar 

  17. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8(1):49–58.

    CAS  Article  PubMed Central  Google Scholar 

  18. Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65(25):2691–8.

    CAS  Article  PubMed Central  Google Scholar 

  19. Pastori D, Farcomeni A, Bucci T, Cangemi R, Ciacci P, Vicario T, et al. Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. Int J Cardiol. 2015;180:1–5.

    Article  PubMed Central  Google Scholar 

  20. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109(12):1509–13.

    Article  PubMed Central  Google Scholar 

  21. Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ, et al. Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol. 2014;7(6):1019–25.

    CAS  Article  PubMed Central  Google Scholar 

  22. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871–8.

    CAS  Article  PubMed Central  Google Scholar 

  23. Qureshi W, O'Neal WT, Soliman EZ, Al-Mallah MH. Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation. Cardiol J. 2016;23(3):333–43.

    Article  PubMed Central  Google Scholar 

  24. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS One. 2018;13(3):e0193924.

    Article  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

  1. Duke Heart Center, Duke University Medical Center, Box 3943, Durham, NC, 27710, USA

    Jeffrey B. Washam

  2. Division of Cardiology, Duke University School of Medicine, Duke Clinical Research Institute, Duke Heart Center, Durham, NC, USA

    Manesh R. Patel

Authors
  1. Jeffrey B. Washam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manesh R. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey B. Washam.

Ethics declarations

Conflict of Interest

Jeffrey B. Washam declares no conflicts of interest.

Manesh R. Patel reports grants and personal fees from Bayer Pharmaceuticals, Janssen, and AstraZeneca; and grants from HeartFlow and NHLBI.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Invasive Electrophysiology and Pacing

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Washam, J.B., Patel, M.R. Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?. Curr Cardiol Rep 20, 105 (2018). https://doi.org/10.1007/s11886-018-1047-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-018-1047-y

Keywords

  • Digoxin
  • Atrial fibrillation